Design, synthesis, and structure - Activity relationships of benzophenone-based tetraamides as novel antibacterial agents

Journal of Medicinal Chemistry

Volumn 52, Issue 16, 2009, Pages 5020-5031

  Vooturi, Sunil K ^a   Cheung, Chrissy M ^a,b   Rybak, Michael J ^a   Firestine, Steven M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPYRROLE DERIVATIVE; 4 BENZAMIDO 1 METHYL N [2 (PIPERIDIN 1 YL)ETHYL] 1H PYRROLE 2 CARBOXAMIDE; 4 BENZAMIDO 1 METHYL N [2 (PYRROLIDIN 1 YL)ETHYL] 1H PYRROLE 2 CARBOXAMIDE; 4 BENZOYL N [2 (PIPERIDIN 1 YL)ETHYL]BENZAMIDE; 4 BENZOYL N [2 (PYRROLIDIN 1 YL)ETHYL]BENZAMIDE; 4,4' (HYDROXYMETHYLENE)BIS[N [2 (PIPERDIN 1 YL)ETHYL]]BENZAMIDE; 4,4' (HYDROXYMETHYLENE)BIS[N [2 (PYRROLIDIN 1 YL)ETHYL]]BENZAMIDE; 4,4' CARBONYLBIS[N (N1,N1 DIMETHYLBENZENE 1,4 DIAMINE) 1H IMIDAZOLE]BENZAMIDE; 4,4' CARBONYLBIS[N (N1,N1 DIMETHYLBENZENE 1,4 DIAMINE) 1H PYRROLE]BENZAMIDE; 4,4' CARBONYLBIS[N (N1,N1 DIMETHYLPROPANE 1,3 DIAMINO) 1H PYRROLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (4 METHYLPIPERAZIN 1 YL)PROPYL] 1H PYRROLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (MORPHOLIN 1 YL)ETHYL] 1H IMIDAZOLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (MORPHOLINO 1 YL)ETHYL] 1H PYRROLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (PIPERDIN 1 YL)ETHYL] 1H IMIDAZOLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (PIPERDIN 1 YL)ETHYL] 1H PYRROLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (PYRROLIDIN 1 YL)ETHYL] 1H IMIDAZOLE]BENZAMIDE; 4,4' CARBONYLBIS[N [2 (PYRROLIDIN 1 YL)ETHYL] 1H PYRROLE]BENZAMIDE; 4,4' METHYLENEBIS[N [2 (PIPERIDIN 1 YL)ETHYL]]BENZAMIDE; 4,4' METHYLENEBIS[N [2 (PYRROLIDIN 1 YL)ETHYL]]BENZAMIDE; AMIDE; ANTIINFECTIVE AGENT; BENZOPHENONE DERIVATIVE; IMIDAZOLE DERIVATIVE; N [3 (DIMETHYLAMINO)PROPYL] 1 METHYL 4 NITRO 1H PYRROLE 2 CARBOXAMIDE; N [4 (DIMETHYLAMINO)PHENYL] 1 METHYL 4 NITRO 1H PYRROLE 2 CARBOXAMIDE; N METHYLIMIDAZOLE DERIVATIVE; N1,N1 BIS[1 METHYL 5 [2 (PYRROLIDIN 1 YL)ETHYLCARBAMOYL] 1H PYRROL 3 YL]UNDECANEDIAMIDE; N1,N11 BIS[1 METHYL 5 [2 (PIPERIDIN 1 YL)ETHYLCARBAMOYL] 1H PYRROL 3 YL]UNDECANEDIAMIDE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MEMBRANE; BINDING AFFINITY; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DESIGN; DRUG DNA BINDING; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BENZOPHENONES; CELL MEMBRANE; CELL WALL; CHO CELLS; CRICETINAE; CRICETULUS; DNA, BACTERIAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; PROTEIN BIOSYNTHESIS; RNA, BACTERIAL; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69049093862     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900519b     Document Type: Article

References (43)

1. Levy, S. B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 2004, 10 (12, Suppl.), S122-S129.
2. Appelbaum, P. C. MRSA - the tip of the iceberg. Clin. Microbiol. Infect. 2006, 12 (Suppl. 2), 3-10.
3. Lode, H. Management of serious nosocomial bacterial infections: do current therapeutic options meet the need? Clin. Microbiol. Infect. 2005, 11 (10), 778-787.
4. Rice, L. B. Unmet medical needs in antibacterial therapy. Biochem. Pharmacol. 2006, 71 (7), 991-995.
5. Spellberg, B.; Powers, J. H.; Brass, E. P.; Miller, L. G.; Edwards J. E., Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 2004, 38 (9), 1279-1286.
6. Alekshun, M. N. New advances in antibiotic development and discovery. Expert Opin. Invest. Drugs 2005, 14 (2), 117-134.
7. National Nosocomial Infections Surveillance (NNIS) system report. Data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 2004, 32 (8), 470-485.
8. Christoffersen, R. E. Antibiotics, an investment worth making? Nat. Biotechnol. 2006, 24 (12), 1512-1514.
9. Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 2007, 3 (9), 541-548.
10. Burli, R. W.; Ge, Y.; White, S.; Baird, E. E.; Touami, S. M.; Taylor, M.; Kaizerman, J. A.; Moser, H. E. DNA binding ligands with excellent antibiotic potency against drug-resistant Gram-positive bacteria. Bioorg. Med. Chem. Lett. 2002, 12 (18), 2591-2594.
11. Burli,R.W.; Jones, P.;McMinn, D.;Le,Q.;Duan, J.X.;Kaizerman, J. A.; Difuntorum, S.; Moser, H. E. DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 2: C-Terminal benzimidazoles and derivatives. Bioorg. Med. Chem. Lett. 2004, 14 (5), 1259-1263.
12. Burli, R. W.; Kaizerman, J. A.; Duan, J. X.; Jones, P.; Johnson, K. W.; Iwamoto, M.; Truong, K.; Hu, W.; Stanton, T.; Chen, A.; Touami, S.; Gross, M.; Jiang, V.; Ge, Y.; Moser, H. E. DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids. Bioorg. Med. Chem. Lett. 2004, 14 (9), 2067-2072.
13. Burli, R. W.; McMinn, D.; Kaizerman, J. A.; Hu, W.; Ge, Y.; Pack, Q.; Jiang, V.; Gross, M.; Garcia, M.; Tanaka, R.; Moser, H. E. DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2004, 14 (5), 1253-1257.
14. Kaizerman, J. A.; Gross, M. I.; Ge, Y.; White, S.; Hu, W.; Duan, J. X.; Baird, E. E.; Johnson, K. W.; Tanaka, R. D.; Moser, H. E.; Burli, R. W. DNA binding ligands targeting drug-resistant bacteria: structure, activity, and pharmacology. J. Med. Chem. 2003, 46 (18), 3914-3929.
15. Khalaf, A. I.; Ebrahimabadi, A. H.; Drummond, A. J.; Anthony, N. G.; Mackay, S. P.; Suckling, C. J.; Waigh, R. D. Synthesis and antimicrobial activity of some netropsin analogues. Org. Biomol. Chem. 2004, 2 (21), 3119-3127.
16. Khalaf, A. I.; Waigh, R. D.; Drummond, A. J.; Pringle, B.; McGroarty, I.; Skellern, G. G.; Suckling, C. J. Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity. J. Med. Chem. 2004, 47 (8), 2133-2156.
17. Marini, N. J.; Baliga, R.; Taylor, M. J.; White, S.; Simpson, P.; Tsai, L.; Baird, E. E. DNA binding hairpin polyamides with antifungal activity. Chem. Biol. 2003, 10 (7), 635-644.
18. Dyatkina, N. B.; Roberts, C. D.; Keicher, J.D.; Dai, Y.;Nadherny, J. P.; Zhang,W.; Schmitz, U.;Kongpachith,A.; Fung,K.; Novikov, A. A.; Lou, L.; Velligan, M.; Khorlin, A. A.; Chen, M. S. Minor grooveDNAbinders as antimicrobial agents. 1. Pyrrole tetraamides are potent antibacterials against vancomycin resistant Enterococci and methicillin resistant Staphylococcus aureus. J. Med. Chem. 2002, 45 (4), 805-817.
19. Hu, W.; Burli, R. W.; Kaizerman, J. A.; Johnson, K. W.; Gross, M. I.; Iwamoto, M.; Jones, P.; Lofland, D.; Difuntorum, S.; Chen, H.; Bozdogan, B.; Appelbaum, P. C.; Moser, H. E. DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus. J. Med. Chem. 2004, 47 (18), 4352-4355.
20. Ge, Y.; Difuntorum, S.; Touami, S.; Critchley, I.; Burli, R.; Jiang, V.; Drazan, K.; Moser, H. In vitro antimicrobial activity of GSQ1530, a new heteroaromatic polycyclic compound. Antimicrob. Agents Chemother. 2002, 46 (10), 3168-3174.
21. Ge, Y.; Wu, J.; White, S. In Mechanistic Study of a New Class Antibiotic HARP, ICAAC: Chicago, IL, 2001; p F-1686.
22. Bednarski, D.; Firestine, S. M. Regulation of transcription by synthetic DNA-bending agents. ChemBioChem 2006, 7 (11), 1715-1721.
23. Dervan, P. B.; Doss, R. M.; Marques, M. A. Programmable DNA binding oligomers for control of transcription. Curr. Med. Chem.: Anti-Cancer Agents 2005, 5 (4), 373-387.
24. Baird, E. E.; Dervan, P. B. Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids. J. Am. Chem. Soc. 1996, 118, 6141-6146.
25. Jaramillo, D.; Liu, Q.; Aldrich-Wright, J.; Tor, Y. Synthesis of N-methylpyrrole and N-methylimidazole amino acids suitable for solid-phase synthesis. J. Org. Chem. 2004, 69 (23), 8151-8153.
26. Fishleigh, R. V.; Fox, K. R.; Khalaf, A. I.; Pitt, A. R.; Scobie, M.; Suckling, C. J.; Urwin, J.; Waigh, R. D.; Young, S. C. DNA binding, solubility, and partitioning characteristics of extended lexitropsins. J. Med. Chem. 2000, 43 (17), 3257-3266.
27. Anthony, N. G.; Breen, D.; Clarke, J.; Donoghue, G.; Drummond, A. J.; Ellis, E. M.; Gemmell, C. G.; Helesbeux, J. J.; Hunter, I. S.; Khalaf, A. I.; Mackay, S. P.; Parkinson, J. A.; Suckling, C. J.; Waigh, R. D. Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups. J. Med. Chem. 2007, 50 (24), 6116-6125.
28. Ianni, A.; Waldovogel, S. R. Reliable and versatile synthesis of 2-aryl substituted cinnamic acid esters. Synthesis 2006, 13, 2103-2112.
29. Hobbs, J. K.; Miller, K.; O'Neill, A. J.; Chopra, I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemother. 2008, 62, 1003-1008.
30. Van Bambeke, F.; Mingeot-Leclercq, M. P.; Struelens, M. J.; Tulkens, P. M. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol. Sci. 2008, 29 (3), 124-134.
31. Som, A.; Vemparala, S.; Ivanov, I.; Tew, G. N. Synthetic mimics of antimicrobial peptides. Biopolymers 2008, 90 (2), 83-93.
32. Toke, O. Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers 2005, 80 (6), 717-735.
33. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005, 3 (3), 238-250.
34. Yeaman, M. R.; Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55 (1), 27-55.
35. Wu, M.; Maier, E.; Benz, R.; Hancock, R. E. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 1999, 38 (22), 7235-7242.
36. Blondelle, S. E.; Lohner, K.; Aguilar, M. Lipid-induced conformation and lipid-binding properties of cytolytic and antimicrobial peptides: determination and biological specificity. Biochim. Biophys. Acta 1999, 1462 (1-2), 89-108.
37. White, D. The Physiology and Biochemistry of Prokaryotes, 3rd ed.; Oxford University Press: New York, 2007.
38. Fischer, W. Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus. Med. Microbiol. Immunol. 1994, 183 (2), 61-76.
39. Zilberstein, D.; Schuldiner, S.; Padan, E. Proton electrochemical gradient in Escherichia coli cells and its relation to active transport of lactose. Biochemistry 1979, 18 (4), 669-673.
40. Hancock,R.E. Peptide antibiotics. Lancet 1997, 349 (9049), 418-422.
41. Zaiou, M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J. Mol. Med. 2007, 85 (4), 317-329.
42. David, S. A. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit. 2001, 14 (6), 370-387.
43. Boger, D.; Fink, B.; Brunette, S.; Tse, W.; Hedrick, M. A simple, high-resolution method for establishing DNA binding affinity and sequence selectivity. J. Am. Chem. Soc. 2001, 123, 5878-5891.